In a historic move reshaping global drug development, the U.S. Food and Drug Administration (FDA) today issued a formal ...

PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of the DurAVR® bIomimetic valve designed for physioloGic flow compared to CoMmercial TAVR devices MINNEAPOLIS and ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the Phase III ALLEGORY study of Gazyva® ...

PITTSBURGH, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS) today reported financial results for the third quarter ending September 30, 2025 and provided a ...

The government shutdown is set to become the longest ever on Wednesday if Congress doesn't reach a deal before then.

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast beginning at ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence platform to transform oncology drug discovery and development, ...

Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the University of North Texas. The symposium, ...

AbbVie's Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the non-segmental ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the ...

The FDA's top drug regulator, Dr. George Tidmarsh, quit after federal officials began reviewing "serious concerns about his ...